116 related articles for article (PubMed ID: 24890286)
1. Frequent activating HRAS mutations in trichilemmoma.
Tsai JH; Huang WC; Jhuang JY; Jeng YM; Cheng ML; Chiu HY; Kuo KT; Liau JY
Br J Dermatol; 2014 Nov; 171(5):1073-7. PubMed ID: 24890286
[TBL] [Abstract][Full Text] [Related]
2. The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer.
Ouerhani S; Elgaaied AB
Cancer Biomark; 2011-2012; 10(6):259-66. PubMed ID: 22820081
[TBL] [Abstract][Full Text] [Related]
3. Phacomatosis pigmentokeratotica is caused by a postzygotic HRAS mutation in a multipotent progenitor cell.
Groesser L; Herschberger E; Sagrera A; Shwayder T; Flux K; Ehmann L; Wollenberg A; Torrelo A; Bagazgoitia L; Diaz-Ley B; Tinschert S; Oschlies I; Singer S; Mickler M; Toll A; Landthaler M; Real FX; Hafner C
J Invest Dermatol; 2013 Aug; 133(8):1998-2003. PubMed ID: 23337891
[TBL] [Abstract][Full Text] [Related]
4. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
[TBL] [Abstract][Full Text] [Related]
5. FGFR3, PIK3CA and RAS mutations in benign lichenoid keratosis.
Groesser L; Herschberger E; Landthaler M; Hafner C
Br J Dermatol; 2012 Apr; 166(4):784-8. PubMed ID: 22188534
[TBL] [Abstract][Full Text] [Related]
6. BRAF, NRAS and HRAS mutations in spitzoid tumours and their possible pathogenetic significance.
Da Forno PD; Pringle JH; Fletcher A; Bamford M; Su L; Potter L; Saldanha G
Br J Dermatol; 2009 Aug; 161(2):364-72. PubMed ID: 19438459
[TBL] [Abstract][Full Text] [Related]
7. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
8. Low incidence of oncogenic EGFR, HRAS, and KRAS mutations in seborrheic keratosis.
Georgieva IA; Mauerer A; Groesser L; Herschberger E; Aslanidis C; Dietmaier W; Landthaler M; Hafner C
Am J Dermatopathol; 2014 Aug; 36(8):635-42. PubMed ID: 23739246
[TBL] [Abstract][Full Text] [Related]
9. PIK3CA, HRAS and KRAS gene mutations in human penile cancer.
Andersson P; Kolaric A; Windahl T; Kirrander P; Söderkvist P; Karlsson MG
J Urol; 2008 May; 179(5):2030-4. PubMed ID: 18355852
[TBL] [Abstract][Full Text] [Related]
10. Recurrent PTPN14 Mutations in Trichilemmoma: Evidence for Distinct Pathways of Molecular Pathogenesis.
Russell-Goldman E; Dong F; Hanna J
Am J Dermatopathol; 2022 Aug; 44(8):545-552. PubMed ID: 35830698
[TBL] [Abstract][Full Text] [Related]
11. KRAS, HRAS and EGFR Mutations in Sporadic Sebaceous Gland Hyperplasia.
Groesser L; Singer S; Peterhof E; Landthaler M; Heigl U; Schneider-Brachert W; Berneburg M; Hafner C
Acta Derm Venereol; 2016 Aug; 96(6):737-41. PubMed ID: 26804118
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
[TBL] [Abstract][Full Text] [Related]
13. Keratinocytic epidermal nevi are associated with mosaic RAS mutations.
Hafner C; Toll A; Gantner S; Mauerer A; Lurkin I; Acquadro F; Fernández-Casado A; Zwarthoff EC; Dietmaier W; Baselga E; Parera E; Vicente A; Casanova A; Cigudosa J; Mentzel T; Pujol RM; Landthaler M; Real FX
J Med Genet; 2012 Apr; 49(4):249-53. PubMed ID: 22499344
[TBL] [Abstract][Full Text] [Related]
14. Naevus sebaceus: a mosaic RASopathy.
Aslam A; Salam A; Griffiths CE; McGrath JA
Clin Exp Dermatol; 2014 Jan; 39(1):1-6. PubMed ID: 24341474
[TBL] [Abstract][Full Text] [Related]
15. Systematised naevus sebaceus resulting from post-zygotic mutation in HRAS.
Hsu CK; Saito R; Nanda A; Rashidghamat E; Al-Ajmi H; Lee JY; Hide M; McGrath JA
Australas J Dermatol; 2017 Feb; 58(1):58-60. PubMed ID: 26400620
[TBL] [Abstract][Full Text] [Related]
16. Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome.
Groesser L; Herschberger E; Ruetten A; Ruivenkamp C; Lopriore E; Zutt M; Langmann T; Singer S; Klingseisen L; Schneider-Brachert W; Toll A; Real FX; Landthaler M; Hafner C
Nat Genet; 2012 Jun; 44(7):783-7. PubMed ID: 22683711
[TBL] [Abstract][Full Text] [Related]
17. Activating mutations in the RAS/mitogen-activated protein kinase signaling pathway in sporadic trichoblastoma and syringocystadenoma papilliferum.
Shen AS; Peterhof E; Kind P; Rütten A; Zelger B; Landthaler M; Berneburg M; Hafner C; Groesser L
Hum Pathol; 2015 Feb; 46(2):272-6. PubMed ID: 25532942
[TBL] [Abstract][Full Text] [Related]
18. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
[TBL] [Abstract][Full Text] [Related]
19. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.
Jebar AH; Hurst CD; Tomlinson DC; Johnston C; Taylor CF; Knowles MA
Oncogene; 2005 Aug; 24(33):5218-25. PubMed ID: 15897885
[TBL] [Abstract][Full Text] [Related]
20. Lack of mutational events of RAS genes in sporadic thyroid cancer but high risk associated with HRAS T81C single nucleotide polymorphism (case-control study).
Khan MS; Pandith AA; Ul Hussain M; Iqbal M; Khan NP; Wani KA; Masoodi SR; Mudassar S
Tumour Biol; 2013 Feb; 34(1):521-9. PubMed ID: 23150177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
